NCT03812549View on ClinicalTrials.gov

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 18, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

July 8, 2022

Conditions
Stage IV NSCLC
Interventions
DRUG

Sintilimab

Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.

RADIATION

stereotactic body radiation therapy

Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f

RADIATION

Low Dose Radiotherapy

LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Sichuan University

OTHER

NCT03812549 - Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients | Biotech Hunter | Biotech Hunter